Details for New Drug Application (NDA): 209956
✉ Email this page to a colleague
The generic ingredient in POMALIDOMIDE is pomalidomide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pomalidomide profile page.
Summary for 209956
Tradename: | POMALIDOMIDE |
Applicant: | Teva Pharms Usa |
Ingredient: | pomalidomide |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 1MG | ||||
Approval Date: | May 4, 2022 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 2MG | ||||
Approval Date: | May 4, 2022 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 3MG | ||||
Approval Date: | May 4, 2022 | TE: | RLD: | No |
Complete Access Available with Subscription